Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNASDAQ:EFTRNASDAQ:NTHINASDAQ:ROSG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.02$0.02$0.06▼$0.33N/AN/A34,287 shsN/AEFTReFFECTOR Therapeutics$0.00+50.0%$0.00$0.00▼$1.47$1K0.223,226 shs28,106 shsNTHINeonc Technologies$6.40-3.2%$7.13$4.11▼$25.00N/AN/A69,201 shs27,734 shsROSG(ROSG)$0.43$0.43$0.23▼$2.75N/AN/A81,512 shs169,599 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition+81.82%+177.14%+280.39%-26.79%-46.41%EFTReFFECTOR Therapeutics0.00%0.00%0.00%-66.67%-99.98%NTHINeonc Technologies-4.48%-10.31%+8.01%+660,999,900.00%+660,999,900.00%ROSG(ROSG)0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AROSG(ROSG)N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AEFTReFFECTOR Therapeutics 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/AROSG(ROSG) 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics$3.55M0.00N/AN/A($1.94) per share0.00NTHINeonc Technologies$79.99KN/AN/AN/AN/AN/AROSG(ROSG)N/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AEFTReFFECTOR Therapeutics-$35.81M-$13.08N/A∞N/AN/AN/AN/A7/28/2025 (Estimated)NTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AROSG(ROSG)N/AN/A0.00∞N/AN/AN/AN/AN/ALatest ROSG, AEHAW, EFTR, and NTHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NTHINeonc TechnologiesN/A-$2.10N/A-$2.10N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AEFTReFFECTOR TherapeuticsN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AROSG(ROSG)N/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AEFTReFFECTOR Therapeutics57.67%NTHINeonc TechnologiesN/AROSG(ROSG)22.80%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AEFTReFFECTOR Therapeutics4.70%NTHINeonc TechnologiesN/AROSG(ROSG)N/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableEFTReFFECTOR Therapeutics104.70 million4.48 millionNo DataNTHINeonc Technologies8N/AN/AN/AROSG(ROSG)N/AN/AN/ANot OptionableROSG, AEHAW, EFTR, and NTHI HeadlinesRecent News About These CompaniesCancer genomics articles from across Nature PortfolioOctober 29, 2024 | nature.comfarting with DIRECT intense eye contact 👀💨 🤣 #shorts #funny #fartprankOctober 7, 2024 | msn.comWhat is Rosh Hashanah? Here's what to know about the Jewish holidayOctober 3, 2024 | yahoo.comInsigniam Consultants Join Prestigious CED Fellowship ProgramSeptember 29, 2024 | msn.comRosetta Green Joins the Seventh EC Framework Program: Receives 0.5 Million Euro Grant to Develop Proteins and Chemicals in Al...August 21, 2024 | br.advfn.comRosetta Genomics Reports Preliminary Data on Discovery of Blood-Based microRNA Signature for Identification and Stratificatio...August 21, 2024 | br.advfn.comAccelerating the Use of Pathogen Genomics and Metagenomics in Public Health: A WorkshopAugust 20, 2024 | nationalacademies.orgThis app’s 52% off and going to make your next vacation so much betterAugust 9, 2024 | nypost.comNvidia's suspected 2025 processor is now rumoured to be built by Intel using off-the-peg Arm cores. Yes, an Nvidia chip built by IntelMay 28, 2024 | msn.comRosetta Genomics Ltd ROSGQFebruary 27, 2024 | morningstar.comGranblue Fantasy: Relink – Rosetta best builds, Skills, and WeaponsFebruary 15, 2024 | videogamer.comPublicis: U.S.-Wide Settlement Agreement Reached Concerning Opioid- Related Work by Rosetta, Bringing to a Close Three Years of DiscussionsFebruary 1, 2024 | pharmiweb.comUsing movies to analyse gene circuit dynamics in single cellsJanuary 10, 2024 | nature.comGenetics and Genomics Virtual Event Series 2016October 18, 2023 | labroots.comLife science company founder: Lowering cost of DNA sequencing leads to groundbreaking advancements in personalized medicineOctober 7, 2023 | bizjournals.comRosh Hashanah 2023 begins tonight: What's a proper Rosh Hashanah greeting?September 15, 2023 | 12news.comWhat Do You Say on Rosh Hashanah? Blessings, Prayers, Greetings for HolidaySeptember 15, 2023 | msn.comRosh Hashanah 2023: What to know about Judaism's holiest daySeptember 15, 2023 | msn.comRosetta Stone Military DiscountJuly 29, 2023 | military.comApple Mac Studio (M2 Ultra, 2023)June 12, 2023 | au.pcmag.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeROSG, AEHAW, EFTR, and NTHI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.02 0.00 (0.00%) As of 06/10/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.eFFECTOR Therapeutics NASDAQ:EFTR$0.0003 +0.00 (+50.00%) As of 12:24 PM EasterneFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.Neonc Technologies NASDAQ:NTHI$6.40 -0.21 (-3.18%) As of 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.(ROSG) NASDAQ:ROSGRosetta Genomics Ltd. provides therapeutic, diagnostic product development and medical research services. The company develops and commercializes new diagnostic tests based on various genomics markers, including DNA, microRNA and protein biomarkers and using various technologies, including, qPCR, microarrays, next generation sequencing and fluorescence in situ hybridization. It offers proprietary microRNA technologies, such as Rosetta Cancer Origin, mi-KIDNEY, and RosettaGX Reveal Test. The company was founded by Isaac Bentwich on March 9, 2000 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ignore the Noise—Samsara Stock Is Still a Strong Buy Oracle’s Cloud Boom Is Just Getting Started Netflix Sets New Highs—Price Targets Keep Climbing IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA Alibaba’s Dip Is a Gift—Here’s the Price That Matters Betting on Disruption: Is Lemonade the Future of Insurance? Starbucks Stock: Culture Fix May Be Key to Long-Term Growth GameStop Turns a Profit, But Core Business Keeps Shrinking Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
